期刊文献+

盐酸阿比朵尔多层缓释片的制备及体内外释放度的评价 被引量:5

Preparation of arbidol hydrochloride multi-layers controlled-released and evaluation of its release rate in vivo and in vitro
暂未订购
导出
摘要 目的:探讨盐酸阿比朵尔多层缓释片的研制及体内外释药评价,为盐酸阿比朵尔多层缓释片的药效学研究提供实验依据。方法:以自制的盐酸阿比朵尔多层缓释片为实验组,以盐酸阿比朵尔单方片剂为对照组,采用高效液相色谱法(HPLC)测定两组实验的体内外释放度,并计算药动学参数及相对生物利用度。结果:盐酸阿比朵尔多层缓释片与盐酸阿比朵尔单方片剂比较,峰浓度Cmax显著降低(P<0.01),达峰时间Tmax明显后移(P<0.01),吸收半衰期T1/2ka和消除半衰期T1/2ke明显延长(P<0.01),峰面积AUC(0-10)显著增加(P<0.01),药物体内平均滞留时间MRT明显延长(P<0.01);其药效可维持12 h以上,相对生物利用度为189.3%。结论:盐酸阿比朵尔多层缓释片制备工艺简单,稳定性好,药效持久,符合设计要求。 Objective To study the development of Arbidol hydrochloride(Ahyd) multi-layers controlled-released preparation and evaluate its release rate in order to provide the basis for Ahyd pharmacodynamics reseach.Methods Ahyd multi-layers was used as experiment group and Ahyd single-layer as control,high performance liquid chromatography(HPLC) was used to examine releasing level of two groups for calculating parameters of drug metabolism and bioavailability.Results Compared with Ahyd single-layer,the multi-layers controlled-released preparation had several significant advantages as below:Cmax fell remarkably(P〈0.01);Tmax,T1/2ka,T1/2ke,AUC(0-10) and(MRT) increased(P〈0.01).The multilayers preparation could maintain 12 h,its relative bioavailability reached 189.3%.Conclusion The multi-layers controlled-released preparation of Ahyd has simple technique,better stability and permanent effect,all of which have met designed requirements.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2009年第4期758-761,共4页 Journal of Jilin University:Medicine Edition
基金 吉林省科技厅科研基金资助课题(20070412)
关键词 盐酸阿比朵尔 多层缓释片 释放度 arbidol hydrochloride multi-layers controlled-released preparation release rate
  • 相关文献

参考文献6

二级参考文献10

  • 1刘宏博,曲文秀,李胜岐,孙继梅,苗里宁,贾冶,张杰,党斌温,李颖,梁瑛,杨京华,张蔚,李永春,潘殿柱.盐酸阿比朵尔片治疗流行性感冒的多中心随机双盲平行对照临床研究[J].中国临床药理学杂志,2006,22(6):403-405. 被引量:28
  • 2杜平.医学实验病毒学[M].人民军医出版社,1985.81-88.
  • 3Shumilov V I, Shuster A M, Lobastov S P, et al. Efficacy of arbidol in prophylaxis and treatment of acute respiratory viral infections in servicemen [J]. Voen Med Zh (Voenno-meditsinskii zhurnal.),2002, 323: 51-3, 96.
  • 4Leneva I,Hay A. The Mechanism of Action of Arbidol Against Influenza Virus. Selection and Characterization of Arbidol-Resistant Mutants[J].Antiviral Research, 1998,37:89.
  • 5Glushkov R G, Gus'kova T A, Krylova Llu, et al. Mechanisms of arbidole's immunomodulating action[J].Vestn Ross Akad Med Nauk,1999,36-40.
  • 6Glushkov RG. Arbidol [J]. Drugs Future, 1992, 17(12): 1079-1081.
  • 7Fedorovskaia EO, Tsyshkova NG, Poverennyi AM, et al. Antimetastatic effects of the new antiviral agent arbidol [J]. Biull Eksp Biol Med (in Russian), 1994, 118 (7) : 80-81.
  • 8Metz R, Muth P, Ferger M, et al. Sensitive high-performance liquid chromatographic determination of arbidol, a new antiviral compound, in human plasma [J]. J Chromatogr A, 1998, 810 (1-2) : 63 - 69.
  • 9申元英,杨占秋,刘建军,邱雨石,肖红,文利,毛琳.大黄提取液抗柯萨奇病毒B_3的实验研究[J].北京中医药大学学报,1999,22(5):65-66. 被引量:18
  • 10祝庆余,秦鄂德,王翠娥,于曼,司炳银,范宝昌,常国辉,彭文明,杨保安,姜涛,李豫川,邓永强,刘洪,甘永华.非典型肺炎病例标本中新型冠状病毒的分离与鉴定[J].中国生物工程杂志,2003,23(4):106-112. 被引量:100

共引文献52

同被引文献73

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部